Wells Fargo analyst Larry Biegelsen maintains $GE HealthCare Technologies (GEHC.US)$ with a buy rating, and maintains the target price at $95.
According to TipRanks data, the analyst has a success rate of 64.8% and a total average return of 11.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GE HealthCare Technologies (GEHC.US)$'s main analysts recently are as follows:
GE HealthCare shares have experienced a 20% increase year-to-date and are approaching all-time highs, currently trading at a premium relative to a close peer. This premium is challenging to justify considering GE HealthCare's relatively lower growth outlook, suggesting that investor expectations may exceed even sell-side consensus. In this context, it is anticipated that GE's growth in the near to medium term may not meet expectations.
GE HealthCare has received positive news from the FDA with the approval of Flurpiridaz, a novel myocardial perfusion imaging positron emission tomography radiopharmaceutical. This product stands out because it is offered as an 'individual dose' prepared in advance, which is a departure from the current standard of on-site dose manufacturing. According to analyst research, Flurpiridaz is expected to deliver significant clinical enhancements over existing MPI radiopharmaceuticals. It is anticipated that adoption by current U.S. cardiac PET centers will be swift and that the availability of Flurpiridaz will substantially widen the reach of U.S. cardiac PET imaging.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富国集团分析师Larry Biegelsen维持$GE HealthCare Technologies (GEHC.US)$买入评级,维持目标价95美元。
根据TipRanks数据显示,该分析师近一年总胜率为64.8%,总平均回报率为11.2%。
此外,综合报道,$GE HealthCare Technologies (GEHC.US)$近期主要分析师观点如下:
GE Healthcare的股价今年迄今已上涨20%,接近历史新高,目前的交易价格相对于接近的同行溢价。考虑到通用电气医疗保健相对较低的增长前景,这种溢价很难证明其合理性,这表明投资者的预期甚至可能超过卖方的共识。在这种情况下,预计通用电气在短期至中期内的增长可能无法达到预期。
随着新型心肌灌注成像正电子发射断层扫描放射药物Flurpiridaz的批准,GE Healthcare收到了来自美国食品药品管理局的积极消息。该产品之所以脱颖而出,是因为它是以事先制备的 “个人剂量” 形式提供的,这与当前的现场剂量制造标准背道而驰。根据分析师的研究,Flurpiridaz有望在现有MPI放射性药物的基础上提供显著的临床改进。预计目前的美国心脏pET中心将迅速采用该技术,Flurpiridaz的上市将大大扩大美国心脏pET成像的覆盖范围。
提示:
TipRanks为独立第三方,提供金融分析师的分析数据,并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议,仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级,分析师星级代表分析师所有推荐的过往表现,通过分析师的总胜率和平均回报率综合计算得出,星星越多,则该分析师过往表现越优异,最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否,取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合,并根据评级变化对组合进行调整,在近一年中该投资组合所获得的回报率。